Comparison of Induction Therapy Using Antithymocyte Globulin and Using Basiliximab for Live Donor Kidney Transplant Recipients: A Single Centre Prospective Cohort Study
| Autor: | Kalpesh Gohel, Sanket S. Patel, Bharat G. Patel |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Pharmacology
medicine.medical_specialty business.industry Basiliximab Incidence (epidemiology) Pharmaceutical Science Renal function 030230 surgery Gastroenterology Transplantation 03 medical and health sciences 0302 clinical medicine Tolerability Internal medicine Cohort medicine Pharmacology (medical) 030212 general & internal medicine business Prospective cohort study Cohort study medicine.drug |
| Zdroj: | Asian Journal of Pharmaceutical and Clinical Research. 9:187 |
| ISSN: | 2455-3891 0974-2441 |
| DOI: | 10.22159/ajpcr.2016.v9i6.14099 |
| Popis: | Objective: Acute rejections (AR) have a negative impact on long-term graft survival and are the major predictor of chronic rejection. Induction therapy is used to reduce AR and prevent delayed graft function (DGF). Antithymocyte globulin (ATG) and basiliximab are mainly used for this purpose. In this prospective, cohort study, we analysed and compared the safety and efficacy of ATG and basiliximab in induction therapy for live donor kidney transplant recipients.Methods: Graft survival, AR-free survival, renal function, DGF and tolerability were compared in patients who underwent live-donor transplantation between January 2014 and August 2014 at Muljibhai Patel Urological Hospital, Nadiad, Gujarat, India.Results and Discussion: A total of 85 live-donor kidney transplant recipients who enrolled were followed up for 12 mo. The incidence of AR was greater in the basiliximab group, as compared with the ATG group (25.6% versus 7.1%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|